|
Originally published In Press as doi:10.1074/jbc.M104467200 on June 11, 2001
J. Biol. Chem., Vol. 276, Issue 32, 30072-30077, August 10, 2001
Amino Acid Determinants in Cyclooxygenase-2 Oxygenation of the
Endocannabinoid 2-Arachidonylglycerol*
Kevin R.
Kozak §,
Jeffery J.
Prusakiewicz §,
Scott W.
Rowlinson ¶,
Claus
Schneider , and
Lawrence J.
Marnett **
From the Departments of Biochemistry and Chemistry,
Vanderbilt-Ingram Cancer Center and Center in Molecular Toxicology and
the Division of Clinical Pharmacology, Vanderbilt University
School of Medicine, Nashville, Tennessee 37232
Received for publication, May 16, 2001
 |
ABSTRACT |
The endocannabinoid,
2-arachidonylglycerol (2-AG), is an endogenous ligand for the central
(CB1) and peripheral (CB2) cannabinoid receptors and has been shown to
be efficiently and selectively oxygenated by cyclooxygenase (COX)-2. We
have investigated 2-AG/COX-2 interactions through site-directed
mutagenesis. An evaluation of more than 20 site-directed mutants of
murine COX-2 has allowed for the development of a model of 2-AG binding
within the COX-2 active site. Most strikingly, these studies have
identified Arg-513 as a critical determinant in the ability of COX-2 to
efficiently generate prostaglandin H2 glycerol
ester, explaining, in part, the observed isoform selectivity for
this substrate. Mutational analysis of Leu-531, an amino acid located
directly across from Arg-513 in the COX-2 active site, suggests that
2-AG is shifted in the active site away from this hydrophobic residue
and toward Arg-513 relative to arachidonic acid. Despite this
difference, aspirin-treated COX-2 oxygenates 2-AG to afford
15-hydroxyeicosatetraenoic acid glycerol ester in a reaction analogous
to the C-15 oxygenation of arachidonic acid observed with
acetylated COX-2. Finally, the differences in substrate binding do not
alter the stereospecificity of the cyclooxygenase reaction;
2-AG-derived and arachidonic acid-derived products share identical stereochemistry.
 |
INTRODUCTION |
Cyclooxygenase (COX; prostaglandin endoperoxide synthase, EC
1.14.99.1)1
bis-dioxygenates arachidonic acid providing prostaglandin
(PG) H2, the precursor to the prostaglandins and
thromboxanes (1). Two cyclooxygenase isoforms exist and differ in their
regulation and tissue distribution (2). COX-1 is a constitutive enzyme expressed in most tissues, whereas COX-2 is inducible and highly regulated by a range of cytokines, growth factors, and tumor promoters (3-7). COX-1 appears to play a role in generating PGs, which serve
cellular "housekeeping" functions and account for PG and thromboxane synthesis in gastric mucosa, kidney, and platelets (8). In
contrast, COX-2 activity is primarily responsible for PG biosynthesis
in the central nervous system and inflammatory cells (9-11). It is now
well established that the two COX isoforms play very different roles in
an array of physiological and pathological processes in
vivo.
The possibility that the different functions of COX enzymes may be
mediated by isoform-specific products has recently been posited (12,
13). For example, the endocannabinoid anandamide has been shown to be
selectively oxygenated by COX-2 generating PG ethanolamides (12). COX-2
also oxygenates the endocannabinoid 2-arachidonylglycerol (2-AG)
providing glycerol esters of both PGs and, to a lesser extent,
hydroxyeicosatetraenoic acids (HETEs). 2-AG oxygenation by COX-2 has
been demonstrated to occur in cultured macrophages. Both human and
murine COX-2 metabolize 2-AG as efficiently as arachidonic acid
(13).
The current study was initiated to define the binding of 2-AG in the
COX-2 active site with a focus on protein residues that account for the
observed isoform selectivity of this substrate. In addition, we
determined the stereochemistry of oxygenation of 2-AG to PG glycerol
esters and HETE glycerol esters (HETE-G) because product
stereochemistry provides additional insight into the nature of
substrate binding within the enzyme active site. These studies allow
the development of a model for 2-AG binding in the COX-2 active site
that helps explain the isoform selectivity of 2-AG oxygenation.
 |
EXPERIMENTAL PROCEDURES |
Materials--
2-AG, PGF2 , PGF2 ,
8-iso-PGF2 , 11 -PGF2 , and
15(R)-PGF2 were purchased from Cayman
Chemical (Ann Arbor, MI). Arachidonic acid was obtained from NuChek
Prep (Elysian, MN). Hematin was purchased from Sigma. All molecular
biology enzymes were obtained from New England Biolabs (Beverly, MA).
Oligonucleotides were purchased from Operon Technologies (Alameda, CA).
Ram seminal vesicles were from Oxford Biomedical Research (Oxford, MI).
All other chemicals were purchased from Aldrich.
Enzymology--
Site-directed mutagenesis of murine COX-2 was
performed as described (14). COX-2 enzymes were expressed in
Sf-9 insect cells by using the pVL1393 transfer vector
(PharMingen, San Diego, CA) and purified by ion-exchange chromatography
and gel filtration as described previously (14). Apoenzymes were
reconstituted with hematin prior to activity assays. COX activity was
quantified as described (15). Initial reaction velocity data were
obtained from the linear portion of oxygen uptake curves. The PG-G to
HETE-G product ratio for enzyme oxygenation of 2-AG was obtained by
incubating 10 µg of protein with 10 µg of endocannabinoid in 150 µl of Tris-HCl buffer (100 mM, pH 8) containing 500 µM phenol for 10 min at 37 °C. Oxygenated products
were extracted with EtOAc. The organic solvent was evaporated under a
stream of argon, and the resultant residue was redissolved in 1:1
H2O:MeCN and analyzed by LC/MS (see below). The PG-G to
HETE-G ratio was calculated by dividing the area of peaks corresponding
to PGE2-G and PGD2-G (m/z
449, M+Na+) by the area of peaks corresponding to 11- and
15-HETE-G (m/z 417, M+Na+) followed
by normalization to the ratio of products generated by wild-type enzyme.
Chemistry--
Acetylation of wild-type murine COX-2 was
accomplished by treating the enzyme with 2 mM aspirin for
30 min at 37 °C. PGF2-G was prepared by incubating 300 µg of 2-AG with 450 µg of heme-reconstituted mCOX-2 in 3.0 ml of Tris-HCl buffer (100 mM, pH 8) containing 500 µM phenol for 2 min at 37 °C followed immediately by
treatment with 3.0 ml of ice-cold EtOAc containing triphenylphosphine
(5 mg/ml). The biphasic mixture was centrifuged, and the organic solvent was removed and dried under a stream of argon. The resultant residue was dissolved in 500 µl of 1:1 H2O:MeCN, filtered
(0.22 µm), and applied to a C18 solid phase extraction column
(Varian, Walnut Creek, CA). PGF2-G was eluted with 1:1
H2O:MeCN. The eluant was lyophilized, and glycerol esters
were saponified by treatment with 1 N NaOH for 1 h at
37 °C. The reaction mixture was acidified with 1 N HCl
and extracted with EtOAc. Thin layer chromatographic analysis was
conducted with a solvent of CHCl3:MeOH:HOAc:H2O
(90:10:1:1), and the products were visualized by iodine staining.
HETE-Gs were prepared by incubating mCOX-2 (500 nM) with
2-AG (50 µM) for 10 min at 37 °C in Tris-HCl buffer
(100 mM, pH 8) containing 500 µM phenol
followed by the addition of ice-cold EtOAc. The biphasic mixture was
centrifuged, and the organic solvent was removed and dried under a
stream of argon. The resultant residue was saponified by treatment with
1 N NaOH for 1 h at 37 °C. The reaction mixture was
acidified with 1 N HCl, and HETEs were extracted with
EtOAc. HETE stereochemistry was established as previously described
(16).
Mass Spectrometry--
LC/MS was conducted as previously
described (13). All displayed chromatograms are representative of at
least three separate experiments.
Molecular Biology--
Polymerase chain reaction (PCR)
primers
(5'-GTCGCAAGCTTGCTGCAGAGTTAGAAGCGCTCTACGGAGACATAGATGC-3'
and
5'-GCTGAGAGCTCGAGGTGTGCATCTTGAACACTGAATGAGGTAAAGGGAC-3') were designed according to Ovis aries COX-2 cDNA
(GenBankTM accession number U68486) and used to amplify a
300-nucleotide fragment from O. aries genomic DNA that
included the codon for residue 513. Genomic DNA was isolated from ram
seminal vesicle tissue with a DNeasy tissue kit (Qiagen, Valencia, CA)
according to the manufacturer's specifications. The primers
encoded for the addition of HinDIII and SacI
restriction sites (underlined above). These enzymes were used to
subclone the PCR product into the pBS+ vector (Stratagene, La Jolla,
CA) for amplification and subsequent sequencing.
Energy Minimization and Modeling--
2-AG was built into the
protein coordinates of uninhibited mCOX-2 (Protein Data Bank code
5COX). All amino acid positions were fixed except for the side chains
of Arg-120, Arg-513, Glu-524, and Tyr-355. The glycerol ester moiety of
2-AG was restrained within 3.6 Å from the hydrogen bond donor/acceptor
groups of Arg-513, Arg-120, and Glu-524. The Tyr-385 hydroxyl group was
restrained within 3.6 Å from C-13 to ensure a productive
conformation for oxygenation. The complexes were energy minimized for
1000 iterations using a conjugate gradient in the consistent valence
forcefield. Molecular dynamic simulations were then run on the energy
minimized assemblies for 1000 iterations at 300 K. All simulations
were performed using the Discover module of Insight II 2000 with a R12000 Silicon Graphics Octane work station.
 |
RESULTS AND DISCUSSION |
Site-directed Mutagenesis and Cyclooxygenase Activity
Assays--
Wild-type and mutant COX-2 enzymes were expressed in
insect cells and then purified by ion exchange and gel filtration. The mutations were made in enzyme residues throughout the cyclooxygenase active site with particular attention paid to amino acids implicated in
arachidonic acid and 2-AG binding (Fig.
1). All of the proteins were shown by
densitometric scanning of SDS-polyacrylamide gels to be at least 80%
pure with the following exceptions: W387F (50%) and Y504F (60%). COX
activity was determined by oxygen uptake. This necessitated the use of
purified proteins to minimize possible hydrolysis of 2-AG to
arachidonic acid by contaminating esterases/lipases.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 1.
Model of arachidonic acid bound in the COX-2
active site. A model of the predicted interactions between
arachidonic acid and the active site residues of mCOX-2 is shown.
|
|
Analyses of COX reaction product profiles typically employ radiolabeled
arachidonic acid substrate and take advantage of the availability of
all necessary synthetic standards. The expense and technical
difficulties associated with the synthesis of the requisite quantity of
radiolabeled 2-AG prevented a similar strategy from being employed in
these studies. Thus, products were identified and quantified by LC/MS
analysis. Fig. 2 shows a typical LC/MS chromatogram for wild-type mCOX-2 incubated with 2-AG.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 2.
Oxygenated products formed by COX-2 action on
2-AG. Selected ion mass chromatograms of oxygenated 2-AG products
generated by wild-type mCOX-2 (10 µg) incubated with an equal mass of
2-AG. The products were eluted with a 15-min gradient of 20-100%
acetonitrile in H2O (0.001% sodium acetate) and detected
by monitoring m/z 449 (top panel) and
417 (bottom panel).
|
|
Constriction Site Mutations--
In both COX isoforms, Arg-120,
Tyr-355, and Glu-524 participate in a hydrogen bonding network that
forms a constriction at the bottom of the substrate (and inhibitor)
binding site (17, 18). In addition to forming the constriction, these
residues play a role in binding the polar carboxylate of both
arachidonic acid and acidic nonsteroidal anti-inflammatory drugs
(19-23). To identify interactions between these residues and 2-AG,
site-directed mutants of mCOX-2 were generated, including R120Q and
R120A, Y355F and Y355A, and E524L. The site-directed mutants R120Q,
Y355F, and E524L displayed modestly reduced capacities to oxygenate
arachidonic acid at high substrate concentrations (<2.5-fold
reductions) (Fig. 3). However, the R120Q
and E524L mutants demonstrated ~9- and 7-fold reductions in 2-AG
oxygenation rates, respectively, when compared with wild-type enzyme
(Fig. 3). In contrast, although Y355F oxygenated arachidonic acid at
approximately half the rate of wild-type enzyme, 2-AG oxygenation
remained essentially unaffected (Fig. 3). A role for Glu-524 in 2-AG
oxygenation is further supported by the demonstration that the E524L
mutant generates a smaller proportion of PG-G products in comparison
with wild-type enzyme (Table I). In
contrast, Tyr-355 mutants actually generate a greater proportion of
PG-G products in comparison with wild-type enzyme (Table I). Taken
together, these results suggest that both Arg-120 and Glu-524 are
critical residues in facilitating 2-AG oxygenation and that Glu-524
plays a role in establishing or maintaining a substrate conformation
that is amenable to cyclization to PG-G products. Tyr-355 appears to be
relatively uninvolved in 2-AG oxygenation because mutations in this
residue do not detract from 2-AG oxygenation rates or PG-G
formation.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 3.
Oxygenation of arachidonic acid and 2-AG by
constriction site mutants of COX-2. Initial O2 uptake
rates by wild-type and mutant murine COX-2 enzymes (200 nM)
with arachidonic acid (100 µM) and 2-AG (200 µM) are shown and are normalized to the initial rate of
O2 uptake for arachidonic acid with wild-type enzyme
(mean ± S.E., n = 3).
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Normalized ratio of PG-G to HETE-G products of 2-AG oxygenation by
mCOX-2 enzymes
The PG-G to HETE-G product ratio was obtained by analyzing products by
LC/MS and was calculated by dividing the area of peaks corresponding to
PGE2-G and PGD2-G (m/z 449, M + Na+) by the area of peaks corresponding to 11- and
15-HETE-G (m/z 417, M + Na+)
followed by normalization to the ratio of products generated by
wild-type enzyme. The values represent the means ± S.E., and the
indicated statistical differences are for comparisons with wild-type
enzyme.
|
|
Side Pocket Mutations--
Previous investigations have identified
the COX-2 side pocket as a structural determinant of the isoform
selectivity observed for 2-AG oxygenation (13). The COX-2 side pocket
is an additional solvent accessible region off the main cyclooxygenase
active site formed by the conserved change of Ile-523 in COX-1 for the
sterically less demanding Val-523 in COX-2 (17, 24). In addition, COX-1 and COX-2 differ in this region at positions 434 and 513. In human and
ovine COX-1, these residues are Ile-434 and His-513, and in all COX-2
genes reported to date these residues are Val-434 and Arg-513 with a
single exception; the reported ovine COX-2 sequence encodes for an
alanine at position 513 (Fig.
4A) (25). To identify the side
pocket residue(s) responsible for the COX-2 selectivity of 2-AG
oxygenation, site-directed mCOX-2 mutants were generated incorporating
conserved COX-2 COX-1 changes. As expected, all side pocket mutants
efficiently oxygenated arachidonic acid (Fig. 5). Investigations into 2-AG oxygenation
began with Val-523 because this residue dictates the COX-2 selectivity
of diarylheterocycle inhibitors such as rofecoxib and celecoxib; the
V523I mutant enzyme is resistant to inhibition by these inhibitors (26,
27). Substitution of Ile for Val-523 only modestly reduced the 2-AG
oxygenation rate (Fig. 5). However, substitution of His for Arg-513
markedly reduced the rate of 2-AG metabolism (Fig. 5). In support of a critical role for Arg-513 and minimal involvement of Val-523 in 2-AG
turnover, the double mutant incorporating both changes was essentially
indistinguishable from the R513H mutant enzyme (Fig. 5). In fact, all
enzymes examined that did not contain Arg at position 513, including
wild-type COX-1 and the triple mutant V523I/R513H/V434I, showed
dramatically reduced activity toward the endocannabinoid (Fig. 5).
Thus, Arg-513 appears, in part, to dictate the isoform selectivity
observed for COX metabolism of 2-AG.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 4.
Sequence alignments for COX-1 and COX-2.
Amino acids 510-535 are shown for all previously reported COX
sequences (A) and the revised ovine COX-2 sequence
(B). Residues 513, 523, and 530 are indicated in
boxes.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 5.
Oxygenation of arachidonic acid and 2-AG by
side pocket mutants of COX-2. Initial O2 uptake rates
by wild-type and mutant murine COX-2 enzymes (200 nM) and
wild-type ovine COX-1 (150 nM) with arachidonic acid (100 µM) and 2-AG (200 µM) are shown and are
normalized to the initial rate of O2 uptake for arachidonic
acid with wild-type enzyme (mean ± S.E., n = 3).
|
|
These and prior results led to the hypothesis that a capacity to
metabolize 2-AG represented an important evolutionary impetus for COX-2
enzymes. To conclude that endocannabinoid metabolism represents a
fundamental COX-2 function, residues critical for endocannabinoid
oxygenase activity should be conserved in all COX-2 enzymes.
Consequently, Arg-513 would be expected to be universally conserved.
The residue at position 513 is Arg in all COX-2 sequences from teleosts
to human except for sheep, which contains an Ala (25). We sought to
confirm the identity of the amino acid at position 513 of sheep COX-2
by PCR analysis of sheep seminal vesicle genomic DNA. Using the
reported sheep COX-2 cDNA sequence as a guide, PCR primers were
designed which, upon amplification, would provide a 300-base pair
fragment spanning the codon for residue 513. PCR amplification of sheep
genomic DNA and subcloning of the subsequent products provided multiple
clones containing the expected size fragment. Sequencing of three
unique clones revealed that residue 513 is an Arg encoded by CGT (Fig.
4B). Thus, Arg-513 appears to be conserved in all known
COX-2 genes, supporting the assertion that this residue may be critical
for COX-2 function.
Taken together these results suggest that three polar residues within
the COX-2 active site, Arg-120, Arg-513, and Glu-524, play critical
roles in promoting 2-AG oxygenation. This endocannabinoid contains
three distinct hydrogen bond donor/acceptors including the two primary
alcohols and the ester carbonyl. Directed by the results of the
site-directed mutagenesis studies, a model for 2-AG binding to COX-2
was developed. Distance restraints were imposed between the three
implicated polar residues in COX-2 and the glycerol moiety of 2-AG, and
molecular dynamic simulations were performed to optimize
substrate-enzyme interactions. These simulations resulted in the
positioning of the ester carbonyl between Arg-120 and Tyr-355. The
calculated distances of the 2-AG carbonyl oxygen from the closest
Arg-120 guanidinium nitrogen and Tyr-355 hydroxyl groups were 3.3 and
2.9 angstroms, respectively. The primary alcohols of 2-AG adopted a
conformation that suggests chelation of the Arg-513 guanidinium group
(Fig. 6). The distances between the two
alcohols of 2-AG and the closest Arg-513 guanidinium nitrogen were
measured to be 2.9 angstroms and 3.2 angstroms. One of these primary
alcohols was located only 3.2 angstroms from the carboxylate moiety of
Glu-524. As shown in Fig. 6, COX-2 accommodates a 2-AG binding
conformation that provides for close interaction between each of
the three polar enzyme residues implicated in 2-AG metabolism and
hydrogen bond donors/acceptors of the endocannabinoid.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 6.
Model of 2-AG bound in the COX-2 active
site. A stereo view of the predicted interactions between 2-AG and
the active site residues of mCOX-2 is shown.
|
|
Hydrophobic Channel Mutations--
Both COX isoforms contain Leu
at position 531 (Fig. 4A). In COX-2, Leu-531 is positioned
directly across from the side pocket in the cyclooxygenase active site
(Fig. 6) (17, 24, 28). Crystallographic analysis of complexes of COX-1
with arachidonic acid indicate that Leu-531 is beyond van der Waals'
contact distances from substrate; however, site-directed mutagenesis
studies demonstrate that this residue promotes high affinity,
productive binding of arachidonic acid within the active site (23, 29).
Reduction of the hydrophobic side chain length at position 531 in COX-1 affects the positioning of arachidonic acid near Arg-120 and
substantially decreases oxygenation rates (29). The demonstrated role
of the COX-2 side pocket, and Arg-513 in particular, in 2-AG
oxygenation suggests that this endocannabinoid may bind nearer the side
pocket and consequently, further from Leu-531 than arachidonic acid. To
test the hypothesis that Leu-531 may have a less significant role in
positioning 2-AG than that seen with arachidonic acid, three mutations
(L531I, L531V, and L531A) were made in mCOX-2 to reduce the size of the
hydrophobic side chain. The ability of these mutant enzymes to
oxygenate both arachidonic acid and 2-AG decreased markedly.
However, the deleterious effects of Leu-531 mutations were less
pronounced with the endocannabinoid substrate. In addition, as the side
chain of residue 531 decreased in size, the ratio of 2-AG/arachidonic
acid oxygenation rates increased (Fig.
7). Thus, changes in Leu-531 of COX-2
affect 2-AG oxygenation rates less significantly than arachidonic acid
oxygenation rates. These results are consistent with our model in which
2-AG is displaced toward the side pocket of COX-2 and away from Leu-531
relative to arachidonic acid (Fig. 6). In fact, modeling results
positioned C-1 of 2-AG 7.3 angstroms from the closest Leu-531
methyl group. In comparison, the crystal structure of arachidonic acid
bound in COX-1 reveals a distance of 4.6 angstroms from C-1 to the
closest Leu-531 methyl group (23).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 7.
Effects of Leu-531 mCOX-2 mutations on
the oxygenation rates of arachidonic acid and 2-AG. The ratio of
initial O2 uptake rates of 2-AG (200 µM)
to arachidonic acid (100 µM) by wild-type and mutant
murine COX-2 enzymes (400 nM) are shown (mean ± S.E.,
n = 3).
|
|
Arachidonic acid binds within COX enzymes in an L-shaped conformation
placing the 13-pro-S-hydrogen close to Tyr-385 and the -end near Gly-533 (14, 23). Previous investigations demonstrated that 2-AG binds within COX-2 in a similar conformation; neither the
G533V nor the Y385F mutant COX-2 enzymes oxygenated 2-AG (13). Residues
Ala-527 and Val-349 line the hydrophobic L-shaped channel adjacent to
Ser-530 (Fig. 6). Ala-527 and Val-349 are within van der Waals'
distances of arachidonic acid, and Val-349 has been implicated in
stabilizing a conformation of arachidonic acid that is optimal for
cyclization (23, 29). Mutations were made in COX-2 at positions 527 and
349 to examine whether these residues also affect 2-AG oxygenation. The
mutant enzymes were incubated with 2-AG, and the products were analyzed
by LC/MS. The A527V and V349I mutations did not show significant
increases in monooxygenated products (Table I). However, V349A and
V349L did show relative increases in monooxygenated products (Table I).
V349L also displayed a dramatic shift in HETE-G regiochemistry, from
C-11 to C-15 (Fig. 8). Therefore, one of
the methyl groups of Val-349 seems to interact with 2-AG to promote
PG-G generation. These findings are consistent with arachidonic acid
product profiles from mutant COX-1 enzymes (29).

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 8.
Generation of 15-HETE-G by V349L mCOX-2.
Selected ion mass chromatograms of HETE-G products generated by
wild-type mCOX-2 (10 µg), V349A mCOX-2 (10 µg), V349I mCOX-2 (10 µg), or V349L mCOX-2 (10 µg) incubated with an equal mass of 2-AG
are shown. HETE-G products were eluted with a 15-min gradient of
20-100% acetonitrile in H2O (0.001% sodium acetate) and
detected by monitoring m/z 417.
|
|
Acetylated COX-2 and S530M Generation of 15-HETE-G--
Both
aspirin-acetylated COX-2 and the S530M enzyme have been shown to
oxygenate arachidonic acid to provide 15-HETE (30-35). These findings
have led to the suggestion that some of the therapeutic actions of
aspirin may be mediated by the generation of 15-HETE and subsequent
metabolites (36). Both 2-AG oxygenation and 15-HETE generation by
acetylated-COX-2 are dependent, in part, on the COX-2 side pocket, and
the possibility existed that these two overlapping spatial requirements
would prevent 2-AG oxygenation by acetylated-COX-2 (35). To assess the
capacity of aspirin-treated COX-2 and the S530M mutant to bind and
metabolize 2-AG, these enzymes were incubated with the endocannabinoid,
and the products were evaluated by LC/MS. Neither enzyme generated a
significant amount of PGE2-G or PGD2-G (data
not shown and Table I). However, HETE-G products were observed, and
regiochemical analysis demonstrated that oxygenation occurred
preferentially at C-15 (Fig. 9). Thus, 2-AG and arachidonic acid are both capable of adopting a conformation in the active site of aspirin-acetylated COX-2, which leads to selective C-15 oxygenation in addition to the more typical conformation in unmodified enzyme that leads preferentially to prostaglandin formation.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 9.
Production of 15-HETE-G by acetylated mCOX-2
and S530M mCOX-2. Selected ion mass chromatograms of HETE-G
products generated by wild-type mCOX-2 (10 µg), acetylated wild-type
mCOX-2 (100 µg), or S530M mCOX-2 (100 µg) incubated with an equal
mass of 2-AG are shown. HETE-G products were eluted with a 15-min
gradient of 20-100% acetonitrile in H2O (0.001% sodium
acetate) and detected by monitoring m/z
417.
|
|
Stereochemistry of Oxygenated 2-AG Products--
COX-2 oxygenation
of anandamide and 2-AG to generate PG ethanolamides and glyceryl PGs
has been reported (12, 13). However, the stereochemistry of the
products has not been conclusively established. Structural changes in
the active site of cyclooxygenase enzymes can lead to altered
product profiles and product stereochemistry. As a result, product
stereochemical analysis provides an additional test of substrate-enzyme
interactions. In addition, PG and HETE stereoisomers generally possess
dramatically different biological activities and/or potencies. For
example, 15(R)-PGF2 displays negligible
binding to rat vascular smooth muscle cells and binds ovine luteal cell
FP receptors with 15-fold less affinity when compared with the natural
stereoisomer (37, 38). Similarly, 8(S)-HETE activates
peroxisome proliferator-activated receptor ~10-fold more potently
than 8(R)-HETE (39). Consequently, we investigated the
relative stereochemistry of PG and HETE glyceryl esters generated by
COX-2 metabolism of 2-AG. PGF2-G was obtained by rapidly
reducing the endoperoxide PGH2-G generated in COX-2 incubations with 2-AG. Following saponification to generate the PGF2-free acid, the sample was analyzed by thin layer
chromatography and compared with PGF2 and diastereomers
(Fig. 10). The sample generated from
2-AG eluted as a single spot with an identical Rf as PGF2 . Under the
chromatographic conditions employed, PGF2 ,
8-iso-PGF2 , 11 -PGF2 , and
15(R)-PGF2 were readily distinguished from
PGF2 . Thus, 2-AG oxygenation by COX-2 provides PG-Gs
with the same relative stereochemistry found for arachidonic
acid-derived PGs. HETE-G stereochemistry also was investigated and
found to be similar to that observed with HETEs generated by
arachidonic acid oxygenation (15-HETE-G, 40 ± 2% R;
11-HETE-G, > 99% R; mean ± S.E.).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 10.
Stereochemistry of 2-AG oxygenation.
A, structures of PGF2 diastereomers.
B, thin layer chromatographic analysis of PGF2
generated by COX-2 oxygenation of 2-AG followed by
triphenylphosphine reduction and saponification
(Sample). The products were visualized by iodine
staining.
|
|
The present results suggest that the COX-2 active site accommodates the
endocannabinoid, 2-AG, in a productive conformation similar to
arachidonic acid; however, subtle differences have been identified. The
endocannabinoid glyceryl moiety interacts with three polar residues in
the COX-2 active site, Arg-120, Arg-513, and Glu-524. The universal
presence of Arg at position 513 in the side pocket of COX-2 enzymes and
its absence in mammalian COX-1 enzymes explains, in part, the isoform
selectivity observed for 2-AG metabolism. When compared with the
binding of arachidonic acid in the COX-1 active site, the polar
terminus of 2-AG shifts toward the COX-2 side pocket and Arg-513 and
away from Leu-531. Despite this difference, 2-AG, like arachidonic
acid, is oxygenated by aspirin-acetylated COX-2 to provide 15-HETE-G
and is bis-dioxygenated by the unmodified enzyme to provide
PG-Gs with the natural prostaglandin stereochemistry. These findings
support the hypothesis that 2-AG is a natural COX-2 substrate and that
the active site of this enzyme has evolved to promote efficient 2-AG turnover.
 |
FOOTNOTES |
*
This work was supported by Grants CA89450, ES00267, CA68484,
and GM07347 from the National Institutes of Health.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
These authors contributed equally to this work.
¶
Present address: Eli Lilly and Company, 355 Merill St.,
Indianapolis, IN 46285.
**
To whom correspondence should be addressed: Dept. of Biochemistry,
Vanderbilt University School of Medicine, Nashville, TN 37232-0146. Tel.: 615-343-7328; Fax: 615-343-7534; E-mail:
marnett@toxicology.mc.vanderbilt.edu.
Published, JBC Papers in Press, June 11, 2001, DOI 10.1074/jbc.M104467200
 |
ABBREVIATIONS |
The abbreviations used are:
COX, cyclooxygenase;
mCOX, murine COX;
AG, arachidonylglycerol;
PG, prostaglandin;
HETE, hydroxyeicosatetraenoic acid;
-G, glyceryl ester;
MS, mass
spectrometry;
LC/MS, liquid chromatography/mass spectrometry;
PCR, polymerase chain reaction.
 |
REFERENCES |
| 1.
|
Hamberg, M.,
and Samuelsson, B.
(1973)
Proc. Natl. Acad. Sci. U. S. A.
70,
899-903
|
| 2.
|
Smith, W. L.,
Garavito, R. M.,
and DeWitt, D. L.
(1996)
J. Biol. Chem.
271,
33157-33160
|
| 3.
|
Evett, G. E.,
Xie, W.,
Chipman, J. G.,
Robertson, D. L.,
and Simmons, D. L.
(1993)
Arch. Biochem. Biophys.
306,
169-177
|
| 4.
|
Herschman, H. R.
(1996)
Biochim. Biophys. Acta
1299,
125-140
|
| 5.
|
Herschman, H. R.,
Xie, W. L.,
and Reddy, S.
(1995)
BioEssays
17,
1031-1037
|
| 6.
|
Smith, W. L.,
and Dewitt, D. L.
(1996)
Adv. Immunol.
62,
167-215
|
| 7.
|
Smith, W. L.,
DeWitt, D. L.,
and Garavito, R. M.
(2000)
Annu. Rev. Biochem.
69,
145-182
|
| 8.
|
Vane, J. R.,
Bakhle, Y. S.,
and Botting, R. M.
(1998)
Annu. Rev. Pharmacol. Toxicol.
38,
97-120
|
| 9.
|
Masferrer, J. L.,
Zweifel, B. S.,
Manning, P. T.,
Hauser, S. D.,
Leahy, K. M.,
Smith, W. G.,
Isakson, P. C.,
and Seibert, K.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
3228-3232
|
| 10.
|
Vane, J. R.,
Mitchell, J. A.,
Appleton, I.,
Tomlinson, A.,
Bishop-Bailey, D.,
Croxtall, J.,
and Willoughby, D. A.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
2046-2050
|
| 11.
|
Kennedy, B. P.,
Chan, C.-C.,
Culp, S. A.,
and Cromlish, W. A.
(1993)
Biochem. Biophys. Res. Commun.
197,
494-500
|
| 12.
|
Yu, M.,
Ives, D.,
and Ramesha, C. S.
(1997)
J. Biol. Chem.
272,
21181-21186
|
| 13.
|
Kozak, K. R.,
Rowlinson, S. W.,
and Marnett, L. J.
(2000)
J. Biol. Chem.
275,
33744-33749
|
| 14.
|
Rowlinson, S. W.,
Crews, B. C.,
Lanzo, C. A.,
and Marnett, L. J.
(1999)
J. Biol. Chem.
274,
23305-23310
|
| 15.
|
Kalgutkar, A. S.,
and Marnett, L. J.
(1994)
Biochemistry
33,
8625-8628
|
| 16.
|
Schneider, C.,
Boeglin, W. E.,
and Brash, A. R.
(2000)
Anal. Biochem.
287,
186-189
|
| 17.
|
Luong, C.,
Miller, A.,
Barnett, J.,
Chow, J.,
Ramesha, C.,
and Browner, M. F.
(1996)
Nat. Struct. Biol.
3,
927-933
|
| 18.
|
Picot, D.,
Loll, P. J.,
and Garavito, R. M.
(1994)
Nature
367,
243-249
|
| 19.
|
Bhattacharyya, D. K.,
Lecomte, M.,
Rieke, C. J.,
Garavito, R. M.,
and Smith, W. L.
(1996)
J. Biol. Chem.
271,
2179-2184
|
| 20.
|
Greig, G. M.,
Francis, D. A.,
Falgueyret, J. P.,
Ouellet, M.,
Percival, M. D.,
Roy, P.,
Bayly, C.,
Mancini, J. A.,
and O'Neill, G. P.
(1997)
Mol. Pharmacol.
52,
829-838
|
| 21.
|
Loll, P. J.,
Picot, D.,
and Garavito, R. M.
(1995)
Nat. Struct. Biol.
2,
637-642
|
| 22.
|
Loll, P. J.,
Picot, D.,
Ekabo, O.,
and Garavito, R. M.
(1996)
Biochemistry
35,
7330-7340
|
| 23.
|
Malkowski, M. G.,
Ginell, S. L.,
Smith, W. L.,
and Garavito, R. M.
(2000)
Science
289,
1933-1937
|
| 24.
|
Kurumbail, R. G.,
Stevens, A. M.,
Gierse, J. K.,
McDonald, J. J.,
Stegeman, R. A.,
Pak, J. Y.,
Gildehaus, D.,
Miyashiro, J. M.,
Penning, T. D.,
Seibert, K.,
Isakson, P. C.,
and Stallings, W. C.
(1996)
Nature
384,
644-648
|
| 25.
|
Zhang, V. V.,
O'Sullivan, M.,
Hussain, H.,
Roswit, W. T.,
and Holtzman, M. J.
(1996)
Biochem. Biophys. Res. Commun.
227,
499-506
|
| 26.
|
Gierse, J. K.,
McDonald, J. J.,
Hauser, S. D.,
Rangwala, S. H.,
Koboldt, C. M.,
and Seibert, K.
(1996)
J. Biol. Chem.
271,
15810-15814
|
| 27.
|
Guo, Q.,
Wang, L.-H.,
Ruan, K.-H.,
and Kulmacz, R. J.
(1996)
J. Biol. Chem.
271,
19134-19139
|
| 28.
|
Kiefer, J. R.,
Pawlitz, J. L.,
Moreland, K. T.,
Stegeman, R. A.,
Hood, W. F.,
Gierse, J. K.,
Stevens, A. M.,
Goodwin, D. C.,
Rowlinson, S. W.,
Marnett, L. J.,
Stallings, W. C.,
and Kurumbail, R. G.
(2000)
Nature
405,
97-101
|
| 29.
|
Thuresson, E. D.,
Lakkides, K. M.,
Rieke, C. J.,
Sun, Y.,
Wingerd, B. A.,
Micielli, R.,
Mulichak, A. M.,
Malkowski, M. G.,
Garavito, R. M.,
and Smith, W. L.
(2001)
J. Biol. Chem.
276,
10347-10357
|
| 30.
|
Meade, E. A.,
Smith, W. L.,
and DeWitt, D. L.
(1993)
J. Biol. Chem.
268,
6610-6614
|
| 31.
|
Lecomte, M.,
Laneuville, O.,
Ji, C.,
DeWitt, D. L.,
and Smith, W. L.
(1994)
J. Biol. Chem.
269,
13207-13215
|
| 32.
|
Xiao, G.,
Tsai, A. L.,
Palmer, G.,
Boyar, W. C.,
Marshall, P. J.,
and Kulmacz, R. J.
(1997)
Biochemistry
36,
1836-1845
|
| 33.
|
Mancini, J. A.,
Vickers, P. J.,
O'Neill, G. P.,
Boily, C.,
Falgueyret, J. P.,
and Riendeau, D.
(1997)
Mol. Pharmacol.
51,
52-60
|
| 34.
|
Schneider, C.,
and Brash, A. R.
(2000)
J. Biol. Chem.
275,
4743-4746
|
| 35.
|
Rowlinson, S. W.,
Crews, B. C.,
Goodwin, D. C.,
Schneider, C.,
Gierse, J. K.,
and Marnett, L. J.
(2000)
J. Biol. Chem.
274,
6586-6591
|
| 36.
|
Serhan, C. N.,
Takano, T.,
Clish, C. B.,
Gronert, K.,
and Petasis, N.
(1999)
Adv. Exp. Med. Biol.
469,
287-293
|
| 37.
|
Balapure, A. K.,
Rexroad, C. E.,
Kawada, K.,
Watt, D. S.,
and Fitz, T. A.
(1989)
Biochem. Pharmacol.
38,
2375-2381
|
| 38.
|
Hanasaki, K.,
Kishi, M.,
and Arita, H.
(1990)
J. Biol. Chem.
265,
4871-4875
|
| 39.
|
Yu, K.,
Bayona, W.,
Kallen, C. B.,
Harding, H. P.,
Ravera, C. P.,
McMahon, G.,
Brown, M.,
and Lazar, M. A.
(1995)
J. Biol. Chem.
270,
23975-23983
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Koszelak-Rosenblum, A. C. Krol, D. M. Simmons, C. C. Goulah, L. Wroblewski, and M. G. Malkowski
His-311 and Arg-559 Are Key Residues Involved in Fatty Acid Oxygenation in Pathogen-inducible Oxygenase
J. Biol. Chem.,
September 5, 2008;
283(36):
24962 - 24971.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Rouzer and L. J. Marnett
Non-redundant Functions of Cyclooxygenases: Oxygenation of Endocannabinoids
J. Biol. Chem.,
March 28, 2008;
283(13):
8065 - 8069.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. V. Frolov, I. G. Berim, and S. Singh
Inhibition of Delayed Rectifier Potassium Channels and Induction of Arrhythmia: A NOVEL EFFECT OF CELECOXIB AND THE MECHANISM UNDERLYING IT
J. Biol. Chem.,
January 18, 2008;
283(3):
1518 - 1524.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ghosh, H. Wang, Y. Ai, E. Romeo, J. P. Luyendyk, J. M. Peters, N. Mackman, S. K. Dey, and T. Hla
COX-2 suppresses tissue factor expression via endocannabinoid-directed PPAR{delta} activation
J. Exp. Med.,
September 3, 2007;
204(9):
2053 - 2061.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Sang, J. Zhang, and C. Chen
PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons
J. Physiol.,
May 1, 2006;
572(3):
735 - 745.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Seibold, T. Ball, L. C. Hsi, D. A. Mills, R. D. Abeysinghe, R. Micielli, C. J. Rieke, R. I. Cukier, and W. L. Smith
Histidine 386 and Its Role in Cyclooxygenase and Peroxidase Catalysis by Prostaglandin-endoperoxide H Synthases
J. Biol. Chem.,
November 14, 2003;
278(46):
46163 - 46170.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. R. Kozak, R. A. Gupta, J. S. Moody, C. Ji, W. E. Boeglin, R. N. DuBois, A. R. Brash, and L. J. Marnett
15-Lipoxygenase Metabolism of 2-Arachidonylglycerol. GENERATION OF A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR alpha AGONIST
J. Biol. Chem.,
June 21, 2002;
277(26):
23278 - 23286.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|